COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
NanoViricides, Inc. announces the start of a Phase II Clinical Trial for NV-387 Oral Gummies as a Treatment for Ebola in DRC. NV-387 offers broad-spectrum antiviral properties against Ebola viruses -
-
-
COMMUNIQUÉ DE PRESSE
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
NanoViricides, Inc. registers successful Phase II Clinical Trial of NV-387 Oral Gummies for Ebola viruses treatment in DRC. Prof. Patrick de Marie Chimusa Katoto leads the trial, expecting dosing in 1-2 weeks -
-
-
COMMUNIQUÉ DE PRESSE
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NanoViricides, Inc. provides an update on its Measles Drug Treatment Program, introducing NV-387 as a potential treatment for Measles outbreak amid rising cases globally
